206 related articles for article (PubMed ID: 34548471)
21. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
[TBL] [Abstract][Full Text] [Related]
22. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
23. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Blombery P; Anderson MA; Gong JN; Thijssen R; Birkinshaw RW; Thompson ER; Teh CE; Nguyen T; Xu Z; Flensburg C; Lew TE; Majewski IJ; Gray DHD; Westerman DA; Tam CS; Seymour JF; Czabotar PE; Huang DCS; Roberts AW
Cancer Discov; 2019 Mar; 9(3):342-353. PubMed ID: 30514704
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
25. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
[TBL] [Abstract][Full Text] [Related]
26. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
[No Abstract] [Full Text] [Related]
28. The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors.
Ko TK; Chuah CT; Huang JW; Ng KP; Ong ST
Oncotarget; 2014 Oct; 5(19):9033-8. PubMed ID: 25333252
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway.
Wu HY; Li KX; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Huang YX
Int Immunopharmacol; 2022 Mar; 104():108497. PubMed ID: 34999394
[TBL] [Abstract][Full Text] [Related]
30. Induction of Cross-resistance to ABCB1 Substrates in Venetoclax-resistant Human Leukemia HL60 Cells.
Nakayama Y; Takara K; Minegaki T; Yamamoto K; Omura T; Yano I
Anticancer Res; 2021 Sep; 41(9):4239-4248. PubMed ID: 34475043
[TBL] [Abstract][Full Text] [Related]
31. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
Nagase R; Inoue D; Pastore A; Fujino T; Hou HA; Yamasaki N; Goyama S; Saika M; Kanai A; Sera Y; Horikawa S; Ota Y; Asada S; Hayashi Y; Kawabata KC; Takeda R; Tien HF; Honda H; Abdel-Wahab O; Kitamura T
J Exp Med; 2018 Jun; 215(6):1729-1747. PubMed ID: 29643185
[No Abstract] [Full Text] [Related]
32. ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia.
Valikhani A; Poopak B; Ferdowsi S; Azizi Tabesh G; Ghaffari SH; Saraf Kazeruoni E; Rezaei N; Farshchi A; Amirizadeh N
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e41-e47. PubMed ID: 27640403
[TBL] [Abstract][Full Text] [Related]
33. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.
Bosc C; Saland E; Bousard A; Gadaud N; Sabatier M; Cognet G; Farge T; Boet E; Gotanègre M; Aroua N; Mouchel PL; Polley N; Larrue C; Kaphan E; Picard M; Sahal A; Jarrou L; Tosolini M; Rambow F; Cabon F; Nicot N; Poillet-Perez L; Wang Y; Su X; Fovez Q; Kluza J; Argüello RJ; Mazzotti C; Avet-Loiseau H; Vergez F; Tamburini J; Fournié JJ; Tiong IS; Wei AH; Kaoma T; Marine JC; Récher C; Stuani L; Joffre C; Sarry JE
Nat Cancer; 2021 Nov; 2(11):1204-1223. PubMed ID: 35122057
[TBL] [Abstract][Full Text] [Related]
34. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
35. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
[TBL] [Abstract][Full Text] [Related]
36. The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.
Xishan Z; Xianjun L; Ziying L; Guangxin C; Gang L
Cancer Gene Ther; 2014 Sep; 21(9):397-404. PubMed ID: 25213664
[TBL] [Abstract][Full Text] [Related]
37. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
[TBL] [Abstract][Full Text] [Related]
38. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.
Bogenberger JM; Delman D; Hansen N; Valdez R; Fauble V; Mesa RA; Tibes R
Leuk Lymphoma; 2015 Jan; 56(1):226-9. PubMed ID: 24707940
[No Abstract] [Full Text] [Related]
39. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells.
Stevens BM; Jones CL; Pollyea DA; Culp-Hill R; D'Alessandro A; Winters A; Krug A; Abbott D; Goosman M; Pei S; Ye H; Gillen AE; Becker MW; Savona MR; Smith C; Jordan CT
Nat Cancer; 2020 Dec; 1(12):1176-1187. PubMed ID: 33884374
[TBL] [Abstract][Full Text] [Related]
40. HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
Takeda R; Asada S; Park SJ; Yokoyama A; Becker HJ; Kanai A; Visconte V; Hershberger C; Hayashi Y; Yonezawa T; Tamura M; Fukushima T; Tanaka Y; Fukuyama T; Matsumoto A; Yamasaki S; Nakai K; Yamazaki S; Inaba T; Shibata T; Inoue D; Honda H; Goyama S; Maciejewski JP; Kitamura T
Blood; 2020 Oct; 136(14):1670-1684. PubMed ID: 32492700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
